Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

L'inotuzumab ozogamicine et la chimiothérapie de première intention dans le traitement des jeunes adultes atteints de leucémie aiguë lymphoblastique B nouvellement diagnostiquée

2 novembre 2026 mis à jour par: Alliance for Clinical Trials in Oncology

Un essai de phase III pour évaluer l'efficacité de l'ajout d'inotuzumab ozogamicine (un anticorps monoclonal anti-CD22 conjugué) au traitement de première ligne chez les jeunes adultes (âgés de 18 à 39 ans) atteints d'une LAL à précurseurs de cellules B nouvellement diagnostiquée

This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy drug called ozogamicin. Inotuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD22 receptors, and delivers ozogamicin to kill them. Chemotherapy drugs, such as [intervention], work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin with chemotherapy may work better in treating young adults with B acute lymphoblastic leukemia.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Description détaillée

PRIMARY OBJECTIVES:

I. To confirm tolerability of the combination regimen with the addition of inotuzumab ozogamicin to the pediatric-inspired regimen of cancer and leukemia group B (CALGB) 10403.

II. To determine whether the addition of inotuzumab ozogamicin significantly improves the event-free survival (EFS) in patients who achieve an induction response achieved with the pediatric-inspired regimen of CALGB 10403, without censoring for transplant. (Phase III) III. To determine the safety and tolerability of a reduced dose of inotuzumab ozogamicin and two cycles of blinatumomab added to the pediatric-inspired regimen of CALGB 10403 (Pilor cohort).

SECONDARY OBJECTIVES:

I. To determine the impact of inotuzumab ozogamicin on disease-free (DFS) and overall survival (OS) in patients who achieve an induction response.

II. To determine whether the addition of inotuzumab ozogamicin significantly improves the event-free survival (EFS) in patients who achieve an induction response achieved with the pediatric-inspired regimen of CALGB 10403, with censoring for transplant.

III. To determine the impact of inotuzumab ozogamicin on minimal residual disease (MRD) and correlate this with the EFS, DFS and OS.

IV. To determine the prognosis based on patients' low-density array (LDA) gene signature in terms of EFS, DFS, and OS after treatment with or without inotuzumab ozogamicin when added to the C10403 backbone regimen.

V. To evaluate the toxicity and tolerability of the addition of inotuzumab ozogamicin to the pediatric-inspired regimen of CALGB 10403.

CORRELATIVE SCIENCE OBJECTIVES:

I. To assess both the correlation of MRD post-induction and at sequential timepoints with LDA signature.

II. To evaluate the influence of MRD status (detectable vs. not and as a continuous measure) in relation to EFS both in the univariate setting as well as adjusting for other clinical features including initial white blood cell (WBC), ethnicity, sex and age at diagnosis.

III. To evaluate the impact of inotuzumab ozogamicin (inotuzumab) on the kinetics of MRD during treatment with inotuzumab in patients randomized to the experimental treatment arm.

IV. To perform genomic analyses to identify and evaluate the incidence and clinical significance of recurring novel fusion genes including those associated with the BCR-ABL1-like signature and to correlate with MRD status, CR rate, EFS and OS.

V. To assess whether rs4958351 is correlated with L-asp allergic reaction in the adolescent and young adult (AYA) population.

VI. To assess the incidence of inherited genetic variants in the GR1A1, CEP72, CPA2, TPMT, NUDT15, GRIN3A, GRIK1, and other genes (which can be found using a whole genome association study [GWAS]), are correlated with increased rates of target toxicities including peripheral neuropathy, hepatotoxicity, pancreatitis, myelosuppression, neurotoxicity, thrombosis, and osteonecrosis, and correlate with treatment discontinuation and other clinical response parameters including complete response (CR) rate, EFS, and OS.

VII. To evaluate asparaginase pharmacokinetics in adolescents and young adults, and investigate its correlation with toxicities and treatment outcomes.

VIII. To investigate the effect of anti-polyethylene glycol (PEG) and anti-agouti signaling protein (ASP) antibodies (PEG-ASP) on ASP enzyme activity.

IX. To measure adherence to oral 6 mercaptopurine (MP) and methotrexate in AYAs with acute lymphoblastic leukemia (ALL) and to examine sociodemographic and behavioral determinants of adherence.

X. To determine the impact of adherence on risk of relapse among AYAs with ALL. XI. To correlate specific karyotype groups (normal or various primary and secondary chromosomal abnormalities) with clinical and laboratory parameters.

XII. To correlate specific karyotype groups with response rates, response duration, survival, and cure in patients treated on this protocol.

XIII. To correlate specific karyotype groups with MRD. XIV. To determine karyotype changes at relapse and the influence of the type of change (or no change) in karyotype at relapse.

XV. To define the rate, analytical performance, and diagnostic yield of ChromoSeq vs. conventional G-banded karyotyping and fluorescence in situ hybridization (FISH) for B ALL patients in a multicenter setting.

OUTLINE:

COURSE I (REMISSION INDUCTION THERAPY): All patients receive allopurinol orally (PO) once daily until peripheral blasts and extramedullary disease are reduced and cytarabine intrathecally (IT) over 1 minute on day 1. Patients also receive daunorubicin hydrochloride intravenously, over 1 to 30 minutes (IV) and vincristine sulfate IV on days 1, 8, 15 and 22, dexamethasone PO or IV twice daily (BID) on days 1-7 and 15-21, pegaspargase for patients >21.5 years IV, over 1 to 2 hours on day 4, 5, or 6, or calaspargase pegol IV, over 1 hour, on days 4, 5 or 6 and methotrexate IT over 1 minute on days 8 and 29. Patients with central nervous system (CNS) 3 disease receive methotrexate IT over 1 minute also on days 15 and 22. All patients then undergo bone marrow aspirate and biopsy on day 29.

Patients enrolled prior to Update 8 with response to remission induction therapy are randomized to 1 of 2 arms. Patients enrolled after amendment 8 are assigned to the pilot cohort. Patients with no response are omitted from the study.

ARM I (CLOSED 7/23/2025):

COURSE II (REMISSION CONSOLIDATION CHEMOTHERAPY): Patients receive cyclophosphamide IV on days 1 and 29, cytarabine IV or SC on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO on days 1-14 and 29-42, and vincristine sulfate IV, over 1 to 10 minutes on days 15, 22, 43, and 50. Patients >21.5 years also receive pegaspargase IV, over 1 to 2 hours, on days 15 and 43 and patients <21.5 years old receive calaspargase pegol IV, over 1 hour, on days 2 and 22, and methotrexate IT on days 1, 8, 15, and 22. Patients with CNS3 receive methotrexate IT only on days 1 and 8. CD20 positive (+) patients receive rituximab IV on days 1, 8, 29, and 36. Patients with evidence of testicular disease at diagnosis also receive radiation therapy (RT). Patients who are MRD+ and CD19+ after completion of this course receive dexamethasone IV or PO on day 1 and blinatumomab IV via continuous infusion on days 1-28, followed by a 14 day break. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo bone marrow aspirate and biopsy on day 56.

COURSE III (INTERIM MAINTENANCE CHEMOTHERAPY): Patients receive vincristine sulfate IV, over 1 to 10 minutes, on days 1, 11, 21, 31, and 41, methotrexate IV, over 24 hours, and IT on days 1, 11, 21, 31, and 41, patients >21.5 years old receive pegaspargase IV, over 1 to 2 hours, and patients < 21.5 years old receive calaspargase pegol IV, over 1 hour on days 2 and 22. CD20+ patients receive rituximab IV on days 1 and 11.

COURSE IV (DELAYED INTENSIFICATION): Patients receive vincristine sulfate IV, over 1 to 10 minutes, on days 1, 8, 15, 43, and 50, dexamethasone PO or IV BID on days 1-7 and 15-21, doxorubicin IV, over 3 to 60 minutes, on days 1, 8, and 15, patients >21.5 years old receive pegaspargase IV, over 1 to 2 hours, on day 4, 5, or 6 and day 43, patients <21.5 years old receive calaspargase pegol IV, over 1 hour, on days 2 and 22. Patients also receive cyclophosphamide IV on day 29, cytarabine IV or SC on days 29-32 and 36-39, thioguanine PO on days 29-42 and methotrexate IT on days 1, 29, and 36. CD20+ patients receive rituximab IV on days 1 and 8. Patients then undergo bone marrow aspirate and biopsy one week after completion of course IV.

COURSE V (MAINTENANCE THERAPY): Patients receive vincristine sulfate IV, over 1 to 10 minutes, on days 1, 29, and 57, dexamethasone PO or IV BID on days 1-5, 29-33, and 57-61, and mercaptopurine PO on days 1-84. Patients also receive methotrexate IT or PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78. Treatment repeats every 12 weeks for up to 3 years in the absence of disease progression or unacceptable toxicity.

Patients undergo multigated acquisition scan (MUGA) or echocardiography and x ray imaging during screening, bone marrow aspiration and biopsy and lumbar puncture and blood sample collection throughout the study.

ARM II (CLOSED 7/23/2025): Patients receive inotuzumab ozogamicin IV, over 1 hour, on days 1, 8, and 15 and undergo bone marrow aspirate and biopsy on day 28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients who are MRD+ and CD19+ after completion of 2 cycles of inotuzumab ozogamicin receive dexamethasone IV or PO on day 1 and blinatumomab IV via continuous infusion on days 1-28, followed by a 14 day break. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive remission consolidated chemotherapy, interim maintenance chemotherapy, delayed intensification, and maintenance therapy as in Arm I.

Patients undergo MUGA or echocardiography and x ray imaging during screening, bone marrow aspiration and biopsy and lumbar puncture and blood sample collection throughout the study.

PILOT COHORT: Patients receive inotuzumab ozogamicin IV, over 1 hour, on days 1, 8, and 15 and undergo bone marrow aspirate and biopsy on day 28.

COURSE II (REMISSION CONSOLIDATION CHEMOTHERAPY): Patients receive cyclophosphamide IV on days 1 and 29, cytarabine IV or SC on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO on days 1-14 and 29-42, and vincristine sulfate IV, over 1 to 10 minutes, on days 15, 22, 43, and 50. Patients > 21.5 years old also receive pegaspargase IV, over 1 to 2 hours, on days 15 and 43 and patients < 21.5 years old receive calaspargase pegol IV, over 1 hour, on days 15 and 43, and methotrexate IT on days 1, 8, 15, and 22. Patients with CNS3 receive methotrexate IT only on days 1 and 8. CD20+ patients receive rituximab IV on days 1, 8, 29, and 36. Patients with evidence of testicular disease at diagnosis also receive RT. Patients then undergo bone marrow aspirate and biopsy on day 56.

BLINATUMOMAB: Patients receive blinatumomab IV, continuously, on days 1-28 of one 42-day cycle in the absence of disease progression or unacceptable toxicity. Patients also receive dexamethasone PO or IV prior to starting the blinatumomab cycle, and a single dose of methotrexate IT between cycle days 29 and 42.

COURSE III (INTERIM MAINTENANCE CHEMOTHERAPY): Patients receive vincristine sulfate IV, over 1 to 10 minutes, on days 1, 11, 21, 31, and 41, methotrexate IV, over 24 hours, and IT on days 1, 11, 21, 31, and 41, patients >21.5 years old receive pegaspargase IV, over 1 to 2 hours, and patients < 21.5 years old receive calaspargase pegol IV, over 1 hour on days 2 and 22. CD20+ patients receive rituximab IV on days 1 and 11.

BLINATUMOMAB: Patients receive blinatumomab IV, continuously, on days 1-28 of one 42-day cycle in the absence of disease progression or unacceptable toxicity. Patients also receive dexamethasone PO or IV prior to starting the blinatumomab cycle, and a single dose of methotrexate IT between cycle days 29 and 42. Patients who are MRD positive and CD19+ after Course II may continue to receive blinatumomab IV, continuously on days 1-28 of each cycle. Cycles repeat every 42 days for an additional 2 cycles in the absence of disease progression or unacceptable toxicity, per investigator discretion.

COURSE IV (DELAYED INTENSIFICATION): Patients receive vincristine sulfate IV, over 1 to 10 minutes on days 1, 8, 15, 43, and 50, dexamethasone PO or IV BID on days 1-7 and 15-21, doxorubicin IV, over 3 to 60 minutes, on days 1, 8, and 15, patients > 21.5 years old receive pegaspargase IV, over 1 to 2 hours, on day 4, 5, or 6 and day 43, patients < 21.5 years old receive calaspargase pegol IV, over 1 hour, on day 4, 5, or 6 and 43. Patients also receive cyclophosphamide IV on day 29, cytarabine IV or SC on days 29-32 and 36-39, thioguanine PO on days 29-42 and methotrexate IT on days 1, 29, and 36. CD20+ patients receive rituximab IV on days 1 and 8. Patients then undergo bone marrow aspirate and biopsy one week after completion of course IV.

COURSE V (MAINTENANCE THERAPY): Patients receive vincristine sulfate IV, over 1 to 10 minutes on days 1, 29, and 57, dexamethasone PO or IV BID on days 1-5, 29-33, and 57-61, and mercaptopurine PO on days 1-84. Patients also receive methotrexate IT on day 1 of cycles 1-4 and PO once weekly (QW) of each cycle. Treatment repeats every 12 weeks for up to 3 years in the absence of disease progression or unacceptable toxicity.

Patients undergo MUGA or echocardiography and x ray imaging during screening, bone marrow aspiration and biopsy and lumbar puncture and blood sample collection throughout the study.

After completion of study treatment, patients are followed up every 2 months for 2 years, every 3 months 2 years, and then every 6 months for up to 10 years.

Type d'étude

Interventionnel

Inscription (Estimé)

303

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

  • Canada
    • Alberta
      • Calgary, Alberta, Canada, T2N 5G2
        • Suspendu
        • Arthur J E Child Comprehensive Cancer Centre
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3E 0V9
        • Suspendu
        • CancerCare Manitoba
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 2Y9
        • Recrutement
        • QEII Health Sciences Centre/Nova Scotia Health Authority
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 902-473-6000
        • Chercheur principal:
          • Nicholas A. Forward
    • Ontario
      • Ottawa, Ontario, Canada, K1H 8L6
        • Recrutement
        • Ottawa Hospital and Cancer Center-General Campus
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 613-761-4395
        • Chercheur principal:
          • Jill Fulcher
    • Quebec
      • Montreal, Quebec, Canada, H3T 1E2
        • Suspendu
        • Jewish General Hospital
  • États-Unis
    • Alabama
      • Birmingham, Alabama, États-Unis, 35233
        • Actif, ne recrute pas
        • University of Alabama at Birmingham Cancer Center
    • Alaska
      • Anchorage, Alaska, États-Unis, 98508
        • Suspendu
        • Anchorage Associates in Radiation Medicine
      • Anchorage, Alaska, États-Unis, 99504
        • Suspendu
        • Anchorage Radiation Therapy Center
      • Anchorage, Alaska, États-Unis, 99508
        • Suspendu
        • Alaska Breast Care and Surgery LLC
      • Anchorage, Alaska, États-Unis, 99508
        • Suspendu
        • Alaska Oncology and Hematology LLC
      • Anchorage, Alaska, États-Unis, 99508
        • Suspendu
        • Alaska Women's Cancer Care
      • Anchorage, Alaska, États-Unis, 99508
        • Suspendu
        • Anchorage Oncology Centre
      • Anchorage, Alaska, États-Unis, 99508
        • Suspendu
        • Katmai Oncology Group
      • Anchorage, Alaska, États-Unis, 99508
        • Suspendu
        • Providence Alaska Medical Center
      • Fairbanks, Alaska, États-Unis, 99701
        • Suspendu
        • Fairbanks Memorial Hospital
    • Arizona
      • Kingman, Arizona, États-Unis, 86401
        • Suspendu
        • Kingman Regional Medical Center
      • Phoenix, Arizona, États-Unis, 85054
        • Suspendu
        • Mayo Clinic Hospital in Arizona
      • Scottsdale, Arizona, États-Unis, 85259
        • Retiré
        • Mayo Clinic in Arizona
    • Arkansas
      • Fort Smith, Arkansas, États-Unis, 72903
        • Suspendu
        • Mercy Hospital Fort Smith
    • California
      • Antioch, California, États-Unis, 94531
        • Recrutement
        • Kaiser Permanente-Deer Valley Medical Center
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jennifer M. Suga
      • Arroyo Grande, California, États-Unis, 93420
        • Suspendu
        • PCR Oncology
      • Burbank, California, États-Unis, 91505
        • Suspendu
        • Providence Saint Joseph Medical Center/Disney Family Cancer Center
      • Clovis, California, États-Unis, 93611
        • Recrutement
        • Community Cancer Institute
        • Chercheur principal:
          • Mohammed S. Bukari
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 559-387-1827
      • Clovis, California, États-Unis, 93611
        • Suspendu
        • University Oncology Associates
      • Costa Mesa, California, États-Unis, 92627
        • Recrutement
        • UC Irvine Health Cancer Center-Newport
        • Chercheur principal:
          • Deepa Jeyakumar
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-827-8839
      • Dublin, California, États-Unis, 94568
        • Recrutement
        • Kaiser Permanente Dublin
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
        • Chercheur principal:
          • Jennifer M. Suga
      • Fremont, California, États-Unis, 94538
        • Recrutement
        • Kaiser Permanente-Fremont
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jennifer M. Suga
      • Fresno, California, États-Unis, 93720
        • Recrutement
        • Kaiser Permanente-Fresno
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jennifer M. Suga
      • Fresno, California, États-Unis, 93720
        • Suspendu
        • Fresno Cancer Center
      • Fresno, California, États-Unis, 93720
        • Recrutement
        • Kaiser Permanente Fresno Orchard Plaza
        • Chercheur principal:
          • Jennifer M. Suga
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 833-574-2273
      • Irvine, California, États-Unis, 92612
        • Recrutement
        • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
        • Chercheur principal:
          • Deepa Jeyakumar
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-827-8839
          • E-mail: ucstudy@uci.edu
      • Modesto, California, États-Unis, 95356
        • Recrutement
        • Kaiser Permanente-Modesto
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jennifer M. Suga
      • Modesto, California, États-Unis, 95356
        • Recrutement
        • Kaiser Permanente- Modesto MOB II
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
        • Chercheur principal:
          • Jennifer M. Suga
      • Oakland, California, États-Unis, 94611
        • Recrutement
        • Kaiser Permanente-Oakland
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jennifer M. Suga
      • Oakland, California, États-Unis, 94611
        • Suspendu
        • Kaiser Permanente Oakland-Broadway
      • Orange, California, États-Unis, 92868
        • Recrutement
        • UC Irvine Health/Chao Family Comprehensive Cancer Center
        • Chercheur principal:
          • Deepa Jeyakumar
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-827-8839
          • E-mail: ucstudy@uci.edu
      • Palo Alto, California, États-Unis, 94304
        • Recrutement
        • Stanford Cancer Institute Palo Alto
        • Chercheur principal:
          • Michaela Liedtke
        • Contact:
      • Rancho Cordova, California, États-Unis, 95670
        • Suspendu
        • Kaiser Permanente-Rancho Cordova Cancer Center
      • Redwood City, California, États-Unis, 94063
        • Suspendu
        • Kaiser Permanente-Redwood City
      • Redwood City, California, États-Unis, 94063
        • Suspendu
        • Kaiser Permanente- Marshall Medical Offices
      • Richmond, California, États-Unis, 94801
        • Recrutement
        • Kaiser Permanente-Richmond
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jennifer M. Suga
      • Rohnert Park, California, États-Unis, 94928
        • Suspendu
        • Rohnert Park Cancer Center
      • Roseville, California, États-Unis, 95661
        • Recrutement
        • Kaiser Permanente-Roseville
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jennifer M. Suga
      • Roseville, California, États-Unis, 95678
        • Suspendu
        • The Permanente Medical Group-Roseville Radiation Oncology
      • Sacramento, California, États-Unis, 95817
        • Recrutement
        • University of California Davis Comprehensive Cancer Center
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 916-734-3089
        • Chercheur principal:
          • Brian A. Jonas
      • Sacramento, California, États-Unis, 95814
        • Recrutement
        • Kaiser Permanente Downtown Commons
        • Chercheur principal:
          • Jennifer M. Suga
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: kpoct@kp.org
      • Sacramento, California, États-Unis, 95823
        • Recrutement
        • Kaiser Permanente-South Sacramento
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jennifer M. Suga
      • Sacramento, California, États-Unis, 95823
        • Suspendu
        • South Sacramento Cancer Center
      • Sacramento, California, États-Unis, 95825
        • Suspendu
        • Kaiser Permanente Sacramento Medical Center
      • San Francisco, California, États-Unis, 94115
        • Recrutement
        • Kaiser Permanente-San Francisco
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jennifer M. Suga
      • San Jose, California, États-Unis, 95119
        • Recrutement
        • Kaiser Permanente-Santa Teresa-San Jose
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jennifer M. Suga
      • San Leandro, California, États-Unis, 94577
        • Recrutement
        • Kaiser Permanente San Leandro
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jennifer M. Suga
      • San Rafael, California, États-Unis, 94903
        • Recrutement
        • Kaiser San Rafael-Gallinas
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jennifer M. Suga
      • San Rafael, California, États-Unis, 94903
        • Suspendu
        • Kaiser Permanente-San Rafael
      • Santa Clara, California, États-Unis, 95051
        • Recrutement
        • Kaiser Permanente Medical Center - Santa Clara
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jennifer M. Suga
      • Santa Rosa, California, États-Unis, 95403
        • Recrutement
        • Kaiser Permanente-Santa Rosa
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jennifer M. Suga
      • South San Francisco, California, États-Unis, 94080
        • Suspendu
        • Kaiser Permanente Cancer Treatment Center
      • South San Francisco, California, États-Unis, 94080
        • Recrutement
        • Kaiser Permanente-South San Francisco
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jennifer M. Suga
      • Stockton, California, États-Unis, 95210
        • Recrutement
        • Kaiser Permanente-Stockton
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jennifer M. Suga
      • Vacaville, California, États-Unis, 95688
        • Recrutement
        • Kaiser Permanente Medical Center-Vacaville
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jennifer M. Suga
      • Vallejo, California, États-Unis, 94589
        • Recrutement
        • Kaiser Permanente-Vallejo
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jennifer M. Suga
      • Walnut Creek, California, États-Unis, 94596
        • Recrutement
        • Kaiser Permanente-Walnut Creek
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jennifer M. Suga
    • Colorado
      • Aurora, Colorado, États-Unis, 80012
        • Suspendu
        • The Medical Center of Aurora
      • Aurora, Colorado, États-Unis, 80012
        • Actif, ne recrute pas
        • Rocky Mountain Cancer Centers-Aurora
      • Boulder, Colorado, États-Unis, 80303
        • Actif, ne recrute pas
        • Boulder Community Foothills Hospital
      • Boulder, Colorado, États-Unis, 80304
        • Actif, ne recrute pas
        • Rocky Mountain Cancer Centers-Boulder
      • Centennial, Colorado, États-Unis, 80112
        • Actif, ne recrute pas
        • Rocky Mountain Cancer Centers - Centennial
      • Denver, Colorado, États-Unis, 80220
        • Suspendu
        • Rose Medical Center
      • Denver, Colorado, États-Unis, 80204
        • Suspendu
        • Cancer Center of Colorado at Sloan's Lake
      • Denver, Colorado, États-Unis, 80206
        • Suspendu
        • National Jewish Health-Main Campus
      • Denver, Colorado, États-Unis, 80218
        • Actif, ne recrute pas
        • Presbyterian - Saint Lukes Medical Center - Health One
      • Denver, Colorado, États-Unis, 80209
        • Actif, ne recrute pas
        • The Women's Imaging Center
      • Denver, Colorado, États-Unis, 80218
        • Actif, ne recrute pas
        • Colorado Blood Cancer Institute
      • Denver, Colorado, États-Unis, 80218
        • Actif, ne recrute pas
        • Rocky Mountain Cancer Centers-Midtown
      • Denver, Colorado, États-Unis, 80220
        • Actif, ne recrute pas
        • Rocky Mountain Cancer Centers-Rose
      • Denver, Colorado, États-Unis, 80220
        • Actif, ne recrute pas
        • Western Surgical Care
      • Denver, Colorado, États-Unis, 80218
        • Suspendu
        • Saint Joseph Hospital - Cancer Centers of Colorado
      • Englewood, Colorado, États-Unis, 80113
        • Suspendu
        • Swedish Medical Center
      • Englewood, Colorado, États-Unis, 80113
        • Actif, ne recrute pas
        • Mountain Blue Cancer Care Center - Swedish
      • Englewood, Colorado, États-Unis, 80113
        • Actif, ne recrute pas
        • Rocky Mountain Cancer Centers - Swedish
      • Englewood, Colorado, États-Unis, 80113
        • Actif, ne recrute pas
        • The Melanoma and Skin Cancer Institute
      • Golden, Colorado, États-Unis, 80401
        • Suspendu
        • National Jewish Health-Western Hematology Oncology
      • Grand Junction, Colorado, États-Unis, 81501
        • Suspendu
        • Saint Mary's Hospital and Regional Medical Center
      • Greeley, Colorado, États-Unis, 80631
        • Suspendu
        • Banner North Colorado Medical Center
      • Lafayette, Colorado, États-Unis, 80026
        • Suspendu
        • Good Samaritan Hospital - Cancer Centers of Colorado
      • Lakewood, Colorado, États-Unis, 80228
        • Actif, ne recrute pas
        • Rocky Mountain Cancer Centers-Lakewood
      • Littleton, Colorado, États-Unis, 80120
        • Actif, ne recrute pas
        • Rocky Mountain Cancer Centers-Littleton
      • Lone Tree, Colorado, États-Unis, 80124
        • Suspendu
        • Sky Ridge Medical Center
      • Lone Tree, Colorado, États-Unis, 80124
        • Actif, ne recrute pas
        • Rocky Mountain Cancer Centers-Sky Ridge
      • Loveland, Colorado, États-Unis, 80539
        • Suspendu
        • Banner North Colorado Medical Center - Loveland Campus
      • Thornton, Colorado, États-Unis, 80260
        • Suspendu
        • National Jewish Health-Northern Hematology Oncology
      • Thornton, Colorado, États-Unis, 80260
        • Actif, ne recrute pas
        • Rocky Mountain Cancer Centers-Thornton
      • Wheat Ridge, Colorado, États-Unis, 80401
        • Suspendu
        • Intermountain Health Lutheran Hospital
    • Connecticut
      • Hartford, Connecticut, États-Unis, 06105
        • Suspendu
        • Smilow Cancer Hospital Care Center at Saint Francis
      • New Haven, Connecticut, États-Unis, 06520
        • Recrutement
        • Yale University
        • Contact:
        • Chercheur principal:
          • Lourdes M. Mendez
      • New Haven, Connecticut, États-Unis, 06510
        • Suspendu
        • Smilow Cancer Center/Yale-New Haven Hospital
    • Florida
      • Fort Lauderdale, Florida, États-Unis, 33308
        • Suspendu
        • Holy Cross Hospital
      • Hollywood, Florida, États-Unis, 33021
        • Recrutement
        • Memorial Regional Hospital/Joe DiMaggio Children's Hospital
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 954-265-1847
          • E-mail: OHR@mhs.net
        • Chercheur principal:
          • Fernando M. Vargas Madueno
      • Miami, Florida, États-Unis, 33176
        • Actif, ne recrute pas
        • Miami Cancer Institute
      • Orlando, Florida, États-Unis, 32806
        • Recrutement
        • Orlando Health Cancer Institute
        • Contact:
        • Chercheur principal:
          • Jose E. Sarriera
      • Pembroke Pines, Florida, États-Unis, 33028
        • Suspendu
        • Memorial Hospital West
    • Georgia
      • Atlanta, Georgia, États-Unis, 30322
        • Recrutement
        • Emory University Hospital/Winship Cancer Institute
        • Chercheur principal:
          • William G. Blum
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 404-778-1868
      • Augusta, Georgia, États-Unis, 30912
        • Recrutement
        • Augusta University Medical Center
        • Chercheur principal:
          • Vamsi Kota
        • Contact:
    • Hawaii
      • Hilo, Hawaii, États-Unis, 96720
        • Suspendu
        • Island Urology-Hilo
      • Honolulu, Hawaii, États-Unis, 96826
        • Recrutement
        • Kapiolani Medical Center for Women and Children
        • Chercheur principal:
          • Craig S. Boddy
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 808-983-6090
      • Honolulu, Hawaii, États-Unis, 96813
        • Suspendu
        • Island Urology
      • Honolulu, Hawaii, États-Unis, 96813
        • Recrutement
        • Straub Clinic and Hospital
        • Chercheur principal:
          • Craig S. Boddy
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 808-522-4333
      • Honolulu, Hawaii, États-Unis, 96813
        • Suspendu
        • Hawaii Cancer Care Inc - Waterfront Plaza
      • Honolulu, Hawaii, États-Unis, 96813
        • Suspendu
        • Queen's Cancer Cenrer - POB I
      • Honolulu, Hawaii, États-Unis, 96813
        • Suspendu
        • Queen's Medical Center
      • Honolulu, Hawaii, États-Unis, 96813
        • Suspendu
        • University of Hawaii Cancer Center
      • Honolulu, Hawaii, États-Unis, 96817
        • Suspendu
        • Hawaii Cancer Care Inc-Liliha
      • Honolulu, Hawaii, États-Unis, 96817
        • Suspendu
        • Kuakini Medical Center
      • Honolulu, Hawaii, États-Unis, 96817
        • Suspendu
        • Queen's Cancer Center - Kuakini
      • Honolulu, Hawaii, États-Unis, 96817
        • Suspendu
        • The Cancer Center of Hawaii-Liliha
      • Honolulu, Hawaii, États-Unis, 96819
        • Suspendu
        • Kaiser Permanente Moanalua Medical Center
      • Lihue, Hawaii, États-Unis, 96766
        • Suspendu
        • Wilcox Memorial Hospital and Kauai Medical Clinic
      • ‘Aiea, Hawaii, États-Unis, 96701
        • Recrutement
        • Pali Momi Medical Center
        • Chercheur principal:
          • Craig S. Boddy
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 808-486-6000
      • ‘Aiea, Hawaii, États-Unis, 96701
        • Suspendu
        • Queen's Cancer Center - Pearlridge
      • ‘Aiea, Hawaii, États-Unis, 96701
        • Suspendu
        • The Cancer Center of Hawaii-Pali Momi
      • ‘Aiea, Hawaii, États-Unis, 96701
        • Suspendu
        • Hawaii Cancer Care - Westridge
    • Idaho
      • Boise, Idaho, États-Unis, 83712
        • Recrutement
        • Saint Luke's Cancer Institute - Boise
        • Chercheur principal:
          • Alison K. Conlin
        • Contact:
      • Boise, Idaho, États-Unis, 83706
        • Recrutement
        • Saint Alphonsus Cancer Care Center-Boise
        • Contact:
        • Chercheur principal:
          • Tareq Al baghdadi
      • Caldwell, Idaho, États-Unis, 83605
        • Recrutement
        • Saint Alphonsus Cancer Care Center-Caldwell
        • Contact:
        • Chercheur principal:
          • Tareq Al baghdadi
      • Coeur d'Alene, Idaho, États-Unis, 83814
        • Recrutement
        • Kootenai Health - Coeur d'Alene
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
      • Emmett, Idaho, États-Unis, 83617
        • Suspendu
        • Walter Knox Memorial Hospital
      • Fruitland, Idaho, États-Unis, 83619
        • Recrutement
        • Saint Luke's Cancer Institute - Fruitland
        • Chercheur principal:
          • Alison K. Conlin
        • Contact:
      • Meridian, Idaho, États-Unis, 83642
        • Suspendu
        • Idaho Urologic Institute-Meridian
      • Meridian, Idaho, États-Unis, 83642
        • Recrutement
        • Saint Luke's Cancer Institute - Meridian
        • Chercheur principal:
          • Alison K. Conlin
        • Contact:
      • Nampa, Idaho, États-Unis, 83687
        • Recrutement
        • Saint Luke's Cancer Institute - Nampa
        • Chercheur principal:
          • Alison K. Conlin
        • Contact:
      • Nampa, Idaho, États-Unis, 83687
        • Recrutement
        • Saint Alphonsus Cancer Care Center-Nampa
        • Contact:
        • Chercheur principal:
          • Tareq Al baghdadi
      • Post Falls, Idaho, États-Unis, 83854
        • Recrutement
        • Kootenai Clinic Cancer Services - Post Falls
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
      • Sandpoint, Idaho, États-Unis, 83864
        • Recrutement
        • Kootenai Clinic Cancer Services - Sandpoint
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
      • Twin Falls, Idaho, États-Unis, 83301
        • Recrutement
        • Saint Luke's Cancer Institute - Twin Falls
        • Chercheur principal:
          • Alison K. Conlin
        • Contact:
    • Illinois
      • Alton, Illinois, États-Unis, 62002
        • Suspendu
        • OSF Saint Anthony's Health Center
      • Burr Ridge, Illinois, États-Unis, 60527
        • Suspendu
        • Loyola Center for Health at Burr Ridge
      • Chicago, Illinois, États-Unis, 60637
        • Recrutement
        • University of Chicago Comprehensive Cancer Center
        • Chercheur principal:
          • Wendy Stock
        • Contact:
      • Chicago, Illinois, États-Unis, 60611
        • Recrutement
        • Northwestern University
        • Chercheur principal:
          • Shira N. Dinner
        • Contact:
      • Chicago, Illinois, États-Unis, 60612
        • Recrutement
        • University of Illinois
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 312-355-3046
        • Chercheur principal:
          • John G. Quigley
      • Chicago, Illinois, États-Unis, 60612
        • Recrutement
        • Rush MD Anderson Cancer Center
        • Contact:
        • Chercheur principal:
          • Melissa L. Larson
      • Evanston, Illinois, États-Unis, 60201
        • Recrutement
        • NorthShore University HealthSystem-Evanston Hospital
        • Chercheur principal:
          • Amy Y. Wang
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 847-570-2109
      • Glenview, Illinois, États-Unis, 60026
        • Recrutement
        • NorthShore University HealthSystem-Glenbrook Hospital
        • Chercheur principal:
          • Amy Y. Wang
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 847-570-2109
      • Highland Park, Illinois, États-Unis, 60035
        • Recrutement
        • NorthShore University HealthSystem-Highland Park Hospital
        • Chercheur principal:
          • Amy Y. Wang
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 847-570-2109
      • Homer Glen, Illinois, États-Unis, 60491
        • Suspendu
        • Loyola Medicine Homer Glen
      • Lake Forest, Illinois, États-Unis, 60045
        • Actif, ne recrute pas
        • Northwestern Medicine Lake Forest Hospital
      • Lisle, Illinois, États-Unis, 60532
        • Suspendu
        • Rush MD Anderson Cancer Center at Rush Lisle
      • Maywood, Illinois, États-Unis, 60153
        • Recrutement
        • Loyola University Medical Center
        • Chercheur principal:
          • Patrick A. Hagen
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 708-226-4357
      • Melrose Park, Illinois, États-Unis, 60160
        • Suspendu
        • Marjorie Weinberg Cancer Center at Loyola-Gottlieb
      • Mount Vernon, Illinois, États-Unis, 62864
        • Suspendu
        • SSM Health Good Samaritan
      • New Lenox, Illinois, États-Unis, 60451
        • Recrutement
        • UC Comprehensive Cancer Center at Silver Cross
        • Chercheur principal:
          • Wendy Stock
        • Contact:
      • Orland Park, Illinois, États-Unis, 60462
        • Recrutement
        • University of Chicago Medicine-Orland Park
        • Chercheur principal:
          • Wendy Stock
        • Contact:
    • Iowa
      • Carroll, Iowa, États-Unis, 51401
        • Actif, ne recrute pas
        • Saint Anthony Regional Hospital
      • Des Moines, Iowa, États-Unis, 50314
        • Actif, ne recrute pas
        • Broadlawns Medical Center
      • Des Moines, Iowa, États-Unis, 50309
        • Actif, ne recrute pas
        • Iowa Methodist Medical Center
      • Des Moines, Iowa, États-Unis, 50316
        • Actif, ne recrute pas
        • Iowa Lutheran Hospital
      • Des Moines, Iowa, États-Unis, 50309
        • Actif, ne recrute pas
        • Blank Children's Hospital
      • Des Moines, Iowa, États-Unis, 50309
        • Actif, ne recrute pas
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
      • Fort Dodge, Iowa, États-Unis, 50501
        • Actif, ne recrute pas
        • UI Healthcare Mission Cancer and Blood - Fort Dodge
      • Iowa City, Iowa, États-Unis, 52242
        • Recrutement
        • University of Iowa/Holden Comprehensive Cancer Center
        • Chercheur principal:
          • Grerk Sutamtewagul
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 800-237-1225
      • West Des Moines, Iowa, États-Unis, 50266-7700
        • Actif, ne recrute pas
        • Methodist West Hospital
    • Kansas
      • Garden City, Kansas, États-Unis, 67846
        • Suspendu
        • Central Care Cancer Center - Garden City
      • Great Bend, Kansas, États-Unis, 67530
        • Suspendu
        • Central Care Cancer Center - Great Bend
      • Kansas City, Kansas, États-Unis, 66160
        • Recrutement
        • University of Kansas Cancer Center
        • Chercheur principal:
          • Kenneth Byrd
        • Contact:
      • Lawrence, Kansas, États-Unis, 66044
        • Suspendu
        • Lawrence Memorial Hospital
      • Westwood, Kansas, États-Unis, 66205
        • Recrutement
        • University of Kansas Hospital-Westwood Cancer Center
        • Chercheur principal:
          • Kenneth Byrd
        • Contact:
      • Wichita, Kansas, États-Unis, 67214
        • Recrutement
        • Cancer Center of Kansas - Wichita
        • Contact:
        • Chercheur principal:
          • Dennis F. Moore
      • Wichita, Kansas, États-Unis, 67208
        • Suspendu
        • Cancer Center of Kansas-Wichita Medical Arts Tower
      • Wichita, Kansas, États-Unis, 67214
        • Suspendu
        • Ascension Via Christi Hospitals Wichita
      • Wichita, Kansas, États-Unis, 67214
        • Suspendu
        • Wesley Medical Center
    • Kentucky
      • Lexington, Kentucky, États-Unis, 40536
        • Recrutement
        • University of Kentucky/Markey Cancer Center
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 859-257-3379
        • Chercheur principal:
          • Ayman Qasrawi
    • Louisiana
      • Baton Rouge, Louisiana, États-Unis, 70809
        • Actif, ne recrute pas
        • Ochsner Health Center-Summa
      • Baton Rouge, Louisiana, États-Unis, 70816
        • Actif, ne recrute pas
        • Medical Center of Baton Rouge
      • Baton Rouge, Louisiana, États-Unis, 70836
        • Actif, ne recrute pas
        • Ochsner High Grove
      • New Orleans, Louisiana, États-Unis, 70121
        • Actif, ne recrute pas
        • Ochsner Medical Center Jefferson
    • Maryland
      • Baltimore, Maryland, États-Unis, 21201
        • Recrutement
        • University of Maryland/Greenebaum Cancer Center
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 800-888-8823
        • Chercheur principal:
          • Shella Saint Fleur-Lominy
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02215
        • Suspendu
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, États-Unis, 02114
        • Suspendu
        • Massachusetts General Hospital Cancer Center
      • Boston, Massachusetts, États-Unis, 02215
        • Suspendu
        • Dana-Farber Cancer Institute
    • Michigan
      • Ann Arbor, Michigan, États-Unis, 48106
        • Recrutement
        • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
        • Contact:
        • Chercheur principal:
          • Tareq Al baghdadi
      • Battle Creek, Michigan, États-Unis, 49017
        • Suspendu
        • Bronson Battle Creek
      • Brighton, Michigan, États-Unis, 48114
        • Recrutement
        • Trinity Health IHA Medical Group Hematology Oncology - Brighton
        • Contact:
        • Chercheur principal:
          • Tareq Al baghdadi
      • Brighton, Michigan, États-Unis, 48114
        • Recrutement
        • Trinity Health Medical Center - Brighton
        • Contact:
        • Chercheur principal:
          • Tareq Al baghdadi
      • Canton, Michigan, États-Unis, 48188
        • Recrutement
        • Trinity Health IHA Medical Group Hematology Oncology - Canton
        • Contact:
        • Chercheur principal:
          • Tareq Al baghdadi
      • Canton, Michigan, États-Unis, 48188
        • Recrutement
        • Trinity Health Medical Center - Canton
        • Contact:
        • Chercheur principal:
          • Tareq Al baghdadi
      • Caro, Michigan, États-Unis, 48723
        • Suspendu
        • Caro Cancer Center
      • Chelsea, Michigan, États-Unis, 48118
        • Recrutement
        • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
        • Contact:
        • Chercheur principal:
          • Tareq Al baghdadi
      • Chelsea, Michigan, États-Unis, 48118
      • Clarkston, Michigan, États-Unis, 48346
        • Suspendu
        • Hematology Oncology Consultants-Clarkston
      • Clarkston, Michigan, États-Unis, 48346
        • Suspendu
        • Newland Medical Associates-Clarkston
      • Detroit, Michigan, États-Unis, 48201
        • Recrutement
        • Wayne State University/Karmanos Cancer Institute
        • Chercheur principal:
          • Jay Yang
        • Contact:
      • Detroit, Michigan, États-Unis, 48236
        • Suspendu
        • Henry Ford Health Saint John Hospital
      • East China Township, Michigan, États-Unis, 48054
        • Suspendu
        • Henry Ford River District Hospital
      • Farmington Hills, Michigan, États-Unis, 48334
        • Recrutement
        • Weisberg Cancer Treatment Center
        • Chercheur principal:
          • Jay Yang
        • Contact:
      • Flint, Michigan, États-Unis, 48503
        • Recrutement
        • Genesys Hurley Cancer Institute
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 810-762-8038
          • E-mail: wstrong@ghci.org
        • Chercheur principal:
          • Tareq Al baghdadi
      • Flint, Michigan, États-Unis, 48503
        • Recrutement
        • Hurley Medical Center
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 810-762-8038
          • E-mail: wstrong@ghci.org
        • Chercheur principal:
          • Tareq Al baghdadi
      • Flint, Michigan, États-Unis, 48503
        • Suspendu
        • Genesee Hematology Oncology PC
      • Flint, Michigan, États-Unis, 48503
        • Recrutement
        • Cancer Hematology Centers - Flint
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 810-762-8038
          • E-mail: wstrong@ghci.org
        • Chercheur principal:
          • Tareq Al baghdadi
      • Grand Rapids, Michigan, États-Unis, 49503
        • Recrutement
        • Trinity Health Grand Rapids Hospital
        • Contact:
        • Chercheur principal:
          • Tareq Al baghdadi
      • Grand Rapids, Michigan, États-Unis, 49503
        • Recrutement
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
        • Contact:
        • Chercheur principal:
          • Kathleen Y. Butler
      • Grand Rapids, Michigan, États-Unis, 49503
        • Suspendu
        • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
      • Grosse Pointe Woods, Michigan, États-Unis, 48236
        • Suspendu
        • Henry Ford Saint John Hospital - Academic
      • Grosse Pointe Woods, Michigan, États-Unis, 48236
        • Suspendu
        • Henry Ford Saint John Hospital - Breast
      • Grosse Pointe Woods, Michigan, États-Unis, 48236
        • Suspendu
        • Henry Ford Saint John Hospital - Van Elslander
      • Kalamazoo, Michigan, États-Unis, 49007
        • Recrutement
        • Bronson Methodist Hospital
        • Contact:
        • Chercheur principal:
          • Kathleen Y. Butler
      • Kalamazoo, Michigan, États-Unis, 49007
        • Recrutement
        • West Michigan Cancer Center
        • Contact:
        • Chercheur principal:
          • Kathleen Y. Butler
      • Kalamazoo, Michigan, États-Unis, 49009
        • Recrutement
        • Beacon Kalamazoo Cancer Center
        • Chercheur principal:
          • Kathleen Y. Butler
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 574-647-7370
      • Kalamazoo, Michigan, États-Unis, 49048
        • Suspendu
        • Beacon Kalamazoo
      • Lansing, Michigan, États-Unis, 48912
        • Suspendu
        • University of Michigan Health - Sparrow Lansing
      • Livonia, Michigan, États-Unis, 48154
        • Suspendu
        • Hope Cancer Clinic
      • Livonia, Michigan, États-Unis, 48154
        • Recrutement
        • Trinity Health Saint Mary Mercy Livonia Hospital
        • Contact:
        • Chercheur principal:
          • Tareq Al baghdadi
      • Macomb, Michigan, États-Unis, 48044
        • Suspendu
        • Henry Ford Warren Hospital - Breast Macomb
      • Macomb, Michigan, États-Unis, 48044
        • Recrutement
        • Henry Ford Saint John Hospital - Macomb Medical
        • Chercheur principal:
          • Tareq Al baghdadi
        • Contact:
      • Marlette, Michigan, États-Unis, 48453
        • Suspendu
        • Saint Mary's Oncology/Hematology Associates of Marlette
      • Muskegon, Michigan, États-Unis, 49444
        • Suspendu
        • Trinity Health Muskegon Hospital
      • Niles, Michigan, États-Unis, 49120
        • Recrutement
        • Corewell Health Lakeland Hospitals - Niles Hospital
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 616-391-1230
        • Chercheur principal:
          • Kathleen Y. Butler
      • Norton Shores, Michigan, États-Unis, 49444
        • Suspendu
        • Cancer and Hematology Centers of Western Michigan - Norton Shores
      • Pontiac, Michigan, États-Unis, 48341
        • Suspendu
        • Hope Cancer Center
      • Pontiac, Michigan, États-Unis, 48341
        • Recrutement
        • Trinity Health Saint Joseph Mercy Oakland Hospital
        • Contact:
        • Chercheur principal:
          • Tareq Al baghdadi
      • Pontiac, Michigan, États-Unis, 48341
        • Suspendu
        • Michigan Healthcare Professionals Pontiac
      • Pontiac, Michigan, États-Unis, 48341
        • Suspendu
        • Trinity Health IHA Medical Group-Alice Gustafson Center
      • Reed City, Michigan, États-Unis, 49677
        • Recrutement
        • Corewell Health Reed City Hospital
        • Contact:
        • Chercheur principal:
          • Kathleen Y. Butler
      • Rochester Hills, Michigan, États-Unis, 48309
        • Suspendu
        • Henry Ford Rochester Hospital
      • Saginaw, Michigan, États-Unis, 48604
        • Suspendu
        • Oncology Hematology Associates of Saginaw Valley PC
      • Saginaw, Michigan, États-Unis, 48601
        • Suspendu
        • MyMichigan Medical Center Saginaw
      • Saint Joseph, Michigan, États-Unis, 49085
        • Recrutement
        • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
        • Contact:
        • Chercheur principal:
          • Kathleen Y. Butler
      • Saint Joseph, Michigan, États-Unis, 49085
        • Suspendu
        • Corewell Health Lakeland Hospitals - Saint Joseph Hospital
      • Sterling Heights, Michigan, États-Unis, 48312
        • Suspendu
        • Bhadresh Nayak MD PC-Sterling Heights
      • Tawas City, Michigan, États-Unis, 48764
        • Suspendu
        • MyMichigan Medical Center Tawas
      • Traverse City, Michigan, États-Unis, 49684
        • Recrutement
        • Munson Medical Center
        • Contact:
        • Chercheur principal:
          • Kathleen Y. Butler
      • Warren, Michigan, États-Unis, 48088
        • Suspendu
        • Advanced Breast Care Center PLLC
      • Warren, Michigan, États-Unis, 48093
        • Suspendu
        • Macomb Hematology Oncology PC
      • Warren, Michigan, États-Unis, 48093
        • Suspendu
        • Henry Ford Madison Heights Hospital - Breast
      • Warren, Michigan, États-Unis, 48093
        • Suspendu
        • Henry Ford Health Warren Hospital
      • Warren, Michigan, États-Unis, 48093
        • Suspendu
        • Henry Ford Warren Hospital - GLCMS
      • West Branch, Michigan, États-Unis, 48661
        • Suspendu
        • Saint Mary's Oncology/Hematology Associates of West Branch
      • Wyoming, Michigan, États-Unis, 49519
        • Recrutement
        • University of Michigan Health - West
        • Contact:
        • Chercheur principal:
          • Kathleen Y. Butler
      • Ypsilanti, Michigan, États-Unis, 48106
      • Ypsilanti, Michigan, États-Unis, 48197
        • Recrutement
        • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
        • Contact:
        • Chercheur principal:
          • Tareq Al baghdadi
    • Minnesota
      • Aitkin, Minnesota, États-Unis, 56431
        • Suspendu
        • Riverwood Healthcare Center
      • Brainerd, Minnesota, États-Unis, 56401
        • Suspendu
        • Essentia Health Saint Joseph's Medical Center
      • Burnsville, Minnesota, États-Unis, 55337
        • Suspendu
        • Fairview Ridges Hospital
      • Burnsville, Minnesota, États-Unis, 55337
        • Suspendu
        • Minnesota Oncology - Burnsville
      • Cambridge, Minnesota, États-Unis, 55008
        • Suspendu
        • Cambridge Medical Center
      • Coon Rapids, Minnesota, États-Unis, 55433
        • Suspendu
        • Mercy Hospital
      • Deer River, Minnesota, États-Unis, 56636
        • Suspendu
        • Essentia Health - Deer River Clinic
      • Detroit Lakes, Minnesota, États-Unis, 56501
        • Suspendu
        • Essentia Health Saint Mary's - Detroit Lakes Clinic
      • Duluth, Minnesota, États-Unis, 55805
        • Recrutement
        • Essentia Health Cancer Center
        • Contact:
        • Chercheur principal:
          • Bret E. Friday
      • Duluth, Minnesota, États-Unis, 55805
        • Suspendu
        • Essentia Health Saint Mary's Medical Center
      • Duluth, Minnesota, États-Unis, 55805
        • Suspendu
        • Miller-Dwan Hospital
      • Edina, Minnesota, États-Unis, 55435
        • Suspendu
        • Fairview Southdale Hospital
      • Fergus Falls, Minnesota, États-Unis, 56537
        • Suspendu
        • Lake Region Healthcare Corporation-Cancer Care
      • Fosston, Minnesota, États-Unis, 56542
        • Suspendu
        • Essentia Health - Fosston
      • Fridley, Minnesota, États-Unis, 55432
        • Actif, ne recrute pas
        • Unity Hospital
      • Hibbing, Minnesota, États-Unis, 55746
        • Suspendu
        • Essentia Health Hibbing Clinic
      • Maple Grove, Minnesota, États-Unis, 55369
        • Suspendu
        • Fairview Clinics and Surgery Center Maple Grove
      • Maplewood, Minnesota, États-Unis, 55109
        • Suspendu
        • Minnesota Oncology Hematology PA-Maplewood
      • Maplewood, Minnesota, États-Unis, 55109
        • Suspendu
        • Saint John's Hospital - Healtheast
      • Minneapolis, Minnesota, États-Unis, 55407
        • Recrutement
        • Abbott-Northwestern Hospital
        • Contact:
        • Chercheur principal:
          • Yan Ji
      • Minneapolis, Minnesota, États-Unis, 55415
        • Suspendu
        • Hennepin County Medical Center
      • Minneapolis, Minnesota, États-Unis, 55454
        • Suspendu
        • Health Partners Inc
      • Monticello, Minnesota, États-Unis, 55362
        • Suspendu
        • Monticello Cancer Center
      • New Ulm, Minnesota, États-Unis, 56073
        • Suspendu
        • New Ulm Medical Center
      • Park Rapids, Minnesota, États-Unis, 56470
        • Suspendu
        • Essentia Health - Park Rapids
      • Princeton, Minnesota, États-Unis, 55371
        • Suspendu
        • Fairview Northland Medical Center
      • Robbinsdale, Minnesota, États-Unis, 55422
        • Suspendu
        • North Memorial Medical Health Center
      • Rochester, Minnesota, États-Unis, 55905
        • Recrutement
        • Mayo Clinic in Rochester
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 855-776-0015
        • Chercheur principal:
          • Aasiya Matin
      • Saint Louis Park, Minnesota, États-Unis, 55416
        • Suspendu
        • Park Nicollet Clinic - Saint Louis Park
      • Saint Paul, Minnesota, États-Unis, 55102
        • Suspendu
        • United Hospital
      • Saint Paul, Minnesota, États-Unis, 55101
        • Suspendu
        • Regions Hospital
      • Sandstone, Minnesota, États-Unis, 55072
        • Suspendu
        • Essentia Health Sandstone
      • Shakopee, Minnesota, États-Unis, 55379
        • Suspendu
        • Saint Francis Regional Medical Center
      • Stillwater, Minnesota, États-Unis, 55082
        • Suspendu
        • Lakeview Hospital
      • Virginia, Minnesota, États-Unis, 55792
        • Suspendu
        • Essentia Health Virginia Clinic
      • Waconia, Minnesota, États-Unis, 55387
        • Suspendu
        • Ridgeview Medical Center
      • Willmar, Minnesota, États-Unis, 56201
        • Suspendu
        • Rice Memorial Hospital
      • Woodbury, Minnesota, États-Unis, 55125
        • Suspendu
        • Minnesota Oncology Hematology PA-Woodbury
      • Wyoming, Minnesota, États-Unis, 55092
        • Suspendu
        • Fairview Lakes Medical Center
    • Missouri
      • Ballwin, Missouri, États-Unis, 63011
        • Suspendu
        • Mercy Oncology and Hematology - Clayton-Clarkson
      • Bolivar, Missouri, États-Unis, 65613
        • Suspendu
        • Central Care Cancer Center - Bolivar
      • Branson, Missouri, États-Unis, 65616
        • Suspendu
        • Cox Cancer Center Branson
      • City of Saint Peters, Missouri, États-Unis, 63376
        • Recrutement
        • Siteman Cancer Center at Saint Peters Hospital
        • Chercheur principal:
          • Geoffrey L. Uy
        • Contact:
      • Creve Coeur, Missouri, États-Unis, 63141
        • Recrutement
        • Siteman Cancer Center at West County Hospital
        • Chercheur principal:
          • Geoffrey L. Uy
        • Contact:
      • Joplin, Missouri, États-Unis, 64804
        • Suspendu
        • Freeman Health System
      • Joplin, Missouri, États-Unis, 64804
        • Suspendu
        • Mercy Hospital Joplin
      • Rolla, Missouri, États-Unis, 65401
        • Suspendu
        • Mercy Clinic-Rolla-Cancer and Hematology
      • Rolla, Missouri, États-Unis, 65401
        • Suspendu
        • Phelps Health Delbert Day Cancer Institute
      • Saint Joseph, Missouri, États-Unis, 64506
        • Suspendu
        • Heartland Regional Medical Center
      • Springfield, Missouri, États-Unis, 65804
        • Suspendu
        • Mercy Hospital Springfield
      • Springfield, Missouri, États-Unis, 65807
        • Suspendu
        • CoxHealth South Hospital
      • St Louis, Missouri, États-Unis, 63110
        • Recrutement
        • Washington University School of Medicine
        • Chercheur principal:
          • Geoffrey L. Uy
        • Contact:
      • St Louis, Missouri, États-Unis, 63128
        • Recrutement
        • Mercy Hospital South
        • Chercheur principal:
          • Jay W. Carlson
        • Contact:
      • St Louis, Missouri, États-Unis, 63141
        • Recrutement
        • Mercy Hospital Saint Louis
        • Chercheur principal:
          • Jay W. Carlson
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 314-251-7066
      • St Louis, Missouri, États-Unis, 63129
        • Recrutement
        • Siteman Cancer Center-South County
        • Chercheur principal:
          • Geoffrey L. Uy
        • Contact:
      • St Louis, Missouri, États-Unis, 63109
        • Suspendu
        • Mercy Infusion Center - Chippewa
      • Washington, Missouri, États-Unis, 63090
        • Suspendu
        • Mercy Hospital Washington
    • Montana
      • Anaconda, Montana, États-Unis, 59711
        • Recrutement
        • Community Hospital of Anaconda
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
      • Billings, Montana, États-Unis, 59101
        • Recrutement
        • Billings Clinic Cancer Center
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
      • Billings, Montana, États-Unis, 59101
        • Suspendu
        • Saint Vincent Healthcare
      • Billings, Montana, États-Unis, 59102
        • Suspendu
        • Saint Vincent Frontier Cancer Center
      • Bozeman, Montana, États-Unis, 59715
        • Recrutement
        • Bozeman Health Deaconess Hospital
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
      • Butte, Montana, États-Unis, 59701
        • Suspendu
        • Saint James Community Hospital and Cancer Treatment Center
      • Great Falls, Montana, États-Unis, 59405
        • Suspendu
        • Great Falls Clinic
      • Great Falls, Montana, États-Unis, 59405
        • Recrutement
        • Benefis Sletten Cancer Institute
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
      • Kalispell, Montana, États-Unis, 59901
        • Recrutement
        • Logan Health Medical Center
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
      • Missoula, Montana, États-Unis, 59802
        • Suspendu
        • Saint Patrick Hospital - Community Hospital
      • Missoula, Montana, États-Unis, 59804
        • Recrutement
        • Community Medical Center
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
    • Nebraska
      • Bellevue, Nebraska, États-Unis, 68123
        • Recrutement
        • Nebraska Medicine-Bellevue
        • Chercheur principal:
          • Krishna Gundabolu
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 402-559-6941
          • E-mail: unmcrsa@unmc.edu
      • Omaha, Nebraska, États-Unis, 68198
        • Recrutement
        • University of Nebraska Medical Center
        • Chercheur principal:
          • Krishna Gundabolu
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 402-559-6941
          • E-mail: unmcrsa@unmc.edu
      • Omaha, Nebraska, États-Unis, 68118
        • Recrutement
        • Nebraska Medicine-Village Pointe
        • Chercheur principal:
          • Krishna Gundabolu
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 402-559-5600
    • Nevada
      • Carson City, Nevada, États-Unis, 89703
        • Suspendu
        • Carson Tahoe Regional Medical Center
      • Henderson, Nevada, États-Unis, 89052
        • Suspendu
        • Cancer and Blood Specialists-Henderson
      • Henderson, Nevada, États-Unis, 89052
        • Suspendu
        • Comprehensive Cancer Centers of Nevada - Henderson
      • Henderson, Nevada, États-Unis, 89052
        • Suspendu
        • Comprehensive Cancer Centers of Nevada-Horizon Ridge
      • Henderson, Nevada, États-Unis, 89052
        • Suspendu
        • Las Vegas Cancer Center-Henderson
      • Henderson, Nevada, États-Unis, 89074
        • Suspendu
        • Comprehensive Cancer Centers of Nevada-Southeast Henderson
      • Henderson, Nevada, États-Unis, 89074
        • Suspendu
        • Las Vegas Urology - Green Valley
      • Henderson, Nevada, États-Unis, 89074
        • Suspendu
        • Las Vegas Urology - Pebble
      • Henderson, Nevada, États-Unis, 89074
        • Suspendu
        • Urology Specialists of Nevada - Green Valley
      • Henderson, Nevada, États-Unis, 89074
        • Suspendu
        • Oncology Las Vegas - Henderson
      • Las Vegas, Nevada, États-Unis, 89102
        • Suspendu
        • Desert West Surgery
      • Las Vegas, Nevada, États-Unis, 89074
        • Suspendu
        • Las Vegas Urology - Pecos
      • Las Vegas, Nevada, États-Unis, 89102
        • Suspendu
        • University Medical Center of Southern Nevada
      • Las Vegas, Nevada, États-Unis, 89103
        • Suspendu
        • Hope Cancer Care of Nevada
      • Las Vegas, Nevada, États-Unis, 89106
        • Suspendu
        • Radiation Oncology Centers of Nevada Central
      • Las Vegas, Nevada, États-Unis, 89106
        • Suspendu
        • Urology Specialists of Nevada - Central
      • Las Vegas, Nevada, États-Unis, 89109
        • Suspendu
        • Sunrise Hospital and Medical Center
      • Las Vegas, Nevada, États-Unis, 89113
        • Suspendu
        • Las Vegas Prostate Cancer Center
      • Las Vegas, Nevada, États-Unis, 89113
        • Suspendu
        • Las Vegas Urology - Sunset
      • Las Vegas, Nevada, États-Unis, 89113
        • Suspendu
        • Urology Specialists of Nevada - Southwest
      • Las Vegas, Nevada, États-Unis, 89119
        • Suspendu
        • Radiation Oncology Centers of Nevada Southeast
      • Las Vegas, Nevada, États-Unis, 89128
        • Suspendu
        • Ann M Wierman MD LTD
      • Las Vegas, Nevada, États-Unis, 89128
        • Suspendu
        • Comprehensive Cancer Centers of Nevada - Northwest
      • Las Vegas, Nevada, États-Unis, 89128
        • Suspendu
        • Las Vegas Urology - Cathedral Rock
      • Las Vegas, Nevada, États-Unis, 89128
        • Suspendu
        • Las Vegas Urology - Smoke Ranch
      • Las Vegas, Nevada, États-Unis, 89128
        • Suspendu
        • OptumCare Cancer Care at MountainView
      • Las Vegas, Nevada, États-Unis, 89128
        • Suspendu
        • Urology Specialists of Nevada - Northwest
      • Las Vegas, Nevada, États-Unis, 89135
        • Suspendu
        • Alliance for Childhood Diseases/Cure 4 the Kids Foundation
      • Las Vegas, Nevada, États-Unis, 89144
        • Suspendu
        • Comprehensive Cancer Centers of Nevada - Town Center
      • Las Vegas, Nevada, États-Unis, 89144
        • Suspendu
        • Comprehensive Cancer Centers of Nevada-Summerlin
      • Las Vegas, Nevada, États-Unis, 89144
        • Suspendu
        • Summerlin Hospital Medical Center
      • Las Vegas, Nevada, États-Unis, 89148-2405
        • Suspendu
        • Las Vegas Cancer Center-Medical Center
      • Las Vegas, Nevada, États-Unis, 89148
        • Suspendu
        • Comprehensive Cancer Centers of Nevada
      • Las Vegas, Nevada, États-Unis, 89169
        • Suspendu
        • Comprehensive Cancer Centers of Nevada - Central Valley
      • Las Vegas, Nevada, États-Unis, 89169
        • Suspendu
        • University Cancer Center
      • Las Vegas, Nevada, États-Unis, 89102
        • Suspendu
        • OptumCare Cancer Care at Charleston
      • Las Vegas, Nevada, États-Unis, 89128
        • Suspendu
        • Oncology Las Vegas - Tenaya
      • Las Vegas, Nevada, États-Unis, 89183
        • Suspendu
        • OptumCare Cancer Care at Fort Apache
      • Pahrump, Nevada, États-Unis, 89048
        • Suspendu
        • Hope Cancer Care of Nevada-Pahrump
      • Reno, Nevada, États-Unis, 89502
        • Suspendu
        • Renown Regional Medical Center
      • Reno, Nevada, États-Unis, 89503
        • Suspendu
        • Saint Mary's Regional Medical Center
      • Reno, Nevada, États-Unis, 89509
        • Suspendu
        • Radiation Oncology Associates
    • New Mexico
      • Albuquerque, New Mexico, États-Unis, 87106
        • Actif, ne recrute pas
        • University of New Mexico Cancer Center
    • New York
      • Buffalo, New York, États-Unis, 14263
        • Recrutement
        • Roswell Park Cancer Institute
        • Chercheur principal:
          • Eunice S. Wang
        • Contact:
      • Lake Success, New York, États-Unis, 11042
        • Recrutement
        • Northwell Health/Center for Advanced Medicine
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 516-734-8896
        • Chercheur principal:
          • Bradley H. Goldberg
      • Manhasset, New York, États-Unis, 11030
        • Recrutement
        • North Shore University Hospital
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 516-734-8896
        • Chercheur principal:
          • Bradley H. Goldberg
      • New Hyde Park, New York, États-Unis, 11040
        • Recrutement
        • Long Island Jewish Medical Center
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 516-734-8896
        • Chercheur principal:
          • Bradley H. Goldberg
      • New York, New York, États-Unis, 10029
        • Recrutement
        • Mount Sinai Hospital
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 212-824-7309
          • E-mail: CCTO@mssm.edu
        • Chercheur principal:
          • Hannah Levavi
      • New York, New York, États-Unis, 10065
        • Recrutement
        • NYP/Weill Cornell Medical Center
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 212-746-1848
        • Chercheur principal:
          • Gail J. Roboz
      • Rochester, New York, États-Unis, 14642
        • Recrutement
        • University of Rochester
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 585-275-5830
        • Chercheur principal:
          • Kristen M. O'Dwyer
      • Stony Brook, New York, États-Unis, 11794
        • Actif, ne recrute pas
        • Stony Brook University Medical Center
      • Syracuse, New York, États-Unis, 13210
        • Actif, ne recrute pas
        • State University of New York Upstate Medical University
      • Verona, New York, États-Unis, 13478
        • Actif, ne recrute pas
        • Upstate Cancer Center at Verona
    • North Carolina
      • Chapel Hill, North Carolina, États-Unis, 27599
        • Recrutement
        • UNC Lineberger Comprehensive Cancer Center
        • Contact:
        • Chercheur principal:
          • Daniel R. Richardson
      • Durham, North Carolina, États-Unis, 27710
        • Actif, ne recrute pas
        • Duke University Medical Center
      • Greenville, North Carolina, États-Unis, 27834
        • Recrutement
        • East Carolina University
        • Chercheur principal:
          • Darla K. Liles
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 252-744-1015
          • E-mail: eubankss@ecu.edu
      • Winston-Salem, North Carolina, États-Unis, 27157
        • Recrutement
        • Wake Forest University Health Sciences
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 336-713-6771
        • Chercheur principal:
          • Bayard L. Powell
    • North Dakota
      • Fargo, North Dakota, États-Unis, 58103
        • Suspendu
        • Essentia Health Cancer Center-South University Clinic
      • Jamestown, North Dakota, États-Unis, 58401
        • Suspendu
        • Essentia Health - Jamestown Clinic
    • Ohio
      • Cincinnati, Ohio, États-Unis, 45219
        • Recrutement
        • University of Cincinnati Cancer Center-UC Medical Center
        • Chercheur principal:
          • Emily K. Curran
        • Contact:
      • Cleveland, Ohio, États-Unis, 44195
        • Recrutement
        • Cleveland Clinic Foundation
        • Contact:
        • Chercheur principal:
          • Anjali S. Advani
      • Cleveland, Ohio, États-Unis, 44106
        • Recrutement
        • Case Western Reserve University
        • Chercheur principal:
          • Brenda W. Cooper
        • Contact:
      • Columbus, Ohio, États-Unis, 43210
        • Recrutement
        • Ohio State University Comprehensive Cancer Center
        • Chercheur principal:
          • Meixiao Long
        • Contact:
      • West Chester, Ohio, États-Unis, 45069
        • Recrutement
        • University of Cincinnati Cancer Center-West Chester
        • Chercheur principal:
          • Emily K. Curran
        • Contact:
    • Oklahoma
      • Oklahoma City, Oklahoma, États-Unis, 73104
        • Recrutement
        • University of Oklahoma Health Sciences Center
        • Contact:
        • Chercheur principal:
          • Mohamad Khawandanah
      • Oklahoma City, Oklahoma, États-Unis, 73120
        • Suspendu
        • Mercy Hospital Oklahoma City
    • Oregon
      • Baker City, Oregon, États-Unis, 97814
        • Suspendu
        • Saint Alphonsus Cancer Care Center-Baker City
      • Bend, Oregon, États-Unis, 97701
        • Suspendu
        • Saint Charles Health System
      • Clackamas, Oregon, États-Unis, 97015
        • Suspendu
        • Clackamas Radiation Oncology Center
      • Clackamas, Oregon, États-Unis, 97015
        • Suspendu
        • Providence Cancer Institute Clackamas Clinic
      • Coos Bay, Oregon, États-Unis, 97420
        • Suspendu
        • Bay Area Hospital
      • Newberg, Oregon, États-Unis, 97132
        • Recrutement
        • Providence Newberg Medical Center
        • Chercheur principal:
          • Alison K. Conlin
        • Contact:
      • Ontario, Oregon, États-Unis, 97914
        • Recrutement
        • Saint Alphonsus Cancer Care Center-Ontario
        • Contact:
        • Chercheur principal:
          • Tareq Al baghdadi
      • Portland, Oregon, États-Unis, 97239
        • Recrutement
        • Oregon Health and Science University
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 503-494-1080
          • E-mail: trials@ohsu.edu
        • Chercheur principal:
          • Brandon M. Hayes-Lattin
      • Portland, Oregon, États-Unis, 97213
        • Recrutement
        • Providence Portland Medical Center
        • Chercheur principal:
          • Alison K. Conlin
        • Contact:
      • Portland, Oregon, États-Unis, 97225
        • Recrutement
        • Providence Saint Vincent Medical Center
        • Chercheur principal:
          • Alison K. Conlin
        • Contact:
      • Redmond, Oregon, États-Unis, 97756
        • Suspendu
        • Saint Charles Health System-Redmond
    • Pennsylvania
      • Allentown, Pennsylvania, États-Unis, 18103
        • Recrutement
        • Lehigh Valley Hospital-Cedar Crest
        • Contact:
        • Chercheur principal:
          • Tareq Al baghdadi
      • Bethlehem, Pennsylvania, États-Unis, 18017
        • Recrutement
        • Lehigh Valley Hospital - Muhlenberg
        • Contact:
        • Chercheur principal:
          • Tareq Al baghdadi
      • East Stroudsburg, Pennsylvania, États-Unis, 18301
        • Suspendu
        • Pocono Medical Center
      • Hazleton, Pennsylvania, États-Unis, 18201
        • Suspendu
        • Lehigh Valley Hospital-Hazleton
      • Philadelphia, Pennsylvania, États-Unis, 19107
        • Recrutement
        • Thomas Jefferson University Hospital
        • Chercheur principal:
          • Lindsay Wilde
        • Contact:
      • Philadelphia, Pennsylvania, États-Unis, 19104
        • Recrutement
        • University of Pennsylvania/Abramson Cancer Center
        • Chercheur principal:
          • Keith W. Pratz
        • Contact:
      • Pittsburgh, Pennsylvania, États-Unis, 15232
        • Actif, ne recrute pas
        • UPMC Hillman Cancer Center
    • Rhode Island
      • Providence, Rhode Island, États-Unis, 02903
        • Recrutement
        • Rhode Island Hospital
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 401-444-1488
        • Chercheur principal:
          • Rabin Niroula
      • Providence, Rhode Island, États-Unis, 02906
        • Suspendu
        • Miriam Hospital
    • South Carolina
      • Boiling Springs, South Carolina, États-Unis, 29316
        • Recrutement
        • Prisma Health Cancer Institute - Spartanburg
        • Chercheur principal:
          • Ki Y. Chung
        • Contact:
      • Clinton, South Carolina, États-Unis, 29325
        • Suspendu
        • Prisma Health Cancer Institute - Laurens
      • Columbia, South Carolina, États-Unis, 29203
        • Recrutement
        • Prisma Health Richland Hospital
        • Chercheur principal:
          • Ki Y. Chung
        • Contact:
      • Easley, South Carolina, États-Unis, 29640
        • Recrutement
        • Prisma Health Cancer Institute - Easley
        • Chercheur principal:
          • Ki Y. Chung
        • Contact:
      • Greenville, South Carolina, États-Unis, 29601
        • Recrutement
        • Saint Francis Hospital
        • Chercheur principal:
          • Stephen H. Dyar
        • Contact:
      • Greenville, South Carolina, États-Unis, 29605
        • Recrutement
        • Prisma Health Cancer Institute - Faris
        • Chercheur principal:
          • Ki Y. Chung
        • Contact:
      • Greenville, South Carolina, États-Unis, 29607
        • Recrutement
        • Saint Francis Cancer Center
        • Chercheur principal:
          • Stephen H. Dyar
        • Contact:
      • Greenville, South Carolina, États-Unis, 29605
        • Recrutement
        • Prisma Health Cancer Institute - Butternut
        • Chercheur principal:
          • Ki Y. Chung
        • Contact:
      • Greenville, South Carolina, États-Unis, 29615
        • Recrutement
        • Prisma Health Cancer Institute - Eastside
        • Chercheur principal:
          • Ki Y. Chung
        • Contact:
      • Greenville, South Carolina, États-Unis, 29605
        • Recrutement
        • Prisma Health Greenville Memorial Hospital
        • Chercheur principal:
          • Ki Y. Chung
        • Contact:
      • Greenville, South Carolina, États-Unis, 29605
        • Suspendu
        • BI-LO Charities Children's Cancer Center
      • Greer, South Carolina, États-Unis, 29650
        • Recrutement
        • Prisma Health Cancer Institute - Greer
        • Chercheur principal:
          • Ki Y. Chung
        • Contact:
      • Seneca, South Carolina, États-Unis, 29672
        • Recrutement
        • Prisma Health Cancer Institute - Seneca
        • Chercheur principal:
          • Ki Y. Chung
        • Contact:
    • Texas
      • Houston, Texas, États-Unis, 77030
        • Recrutement
        • Houston Methodist Hospital
        • Chercheur principal:
          • Siddhartha Ganguly
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 713-790-2700
      • Lubbock, Texas, États-Unis, 79410
        • Actif, ne recrute pas
        • Covenant Medical Center-Lakeside
    • Utah
      • American Fork, Utah, États-Unis, 84003
        • Suspendu
        • American Fork Hospital / Huntsman Intermountain Cancer Center
      • Cedar City, Utah, États-Unis, 84720
        • Suspendu
        • Sandra L Maxwell Cancer Center
      • Logan, Utah, États-Unis, 84321
        • Suspendu
        • Logan Regional Hospital
      • Murray, Utah, États-Unis, 84107
        • Suspendu
        • Intermountain Medical Center
      • Ogden, Utah, États-Unis, 84403
        • Suspendu
        • McKay-Dee Hospital Center
      • Provo, Utah, États-Unis, 84604
        • Suspendu
        • Utah Valley Regional Medical Center
      • Riverton, Utah, États-Unis, 84065
        • Suspendu
        • Riverton Hospital
      • Salt Lake City, Utah, États-Unis, 84112
        • Recrutement
        • Huntsman Cancer Institute/University of Utah
        • Contact:
        • Chercheur principal:
          • Paul J. Shami
      • Salt Lake City, Utah, États-Unis, 84106
        • Suspendu
        • Utah Cancer Specialists-Salt Lake City
      • Salt Lake City, Utah, États-Unis, 84143
        • Suspendu
        • LDS Hospital
      • St. George, Utah, États-Unis, 84770
        • Suspendu
        • Saint George Regional Medical Center
    • Virginia
      • Fairfax, Virginia, États-Unis, 22031
        • Actif, ne recrute pas
        • Inova Schar Cancer Institute
      • Falls Church, Virginia, États-Unis, 22042
        • Actif, ne recrute pas
        • Inova Fairfax Hospital
      • Richmond, Virginia, États-Unis, 23298
        • Recrutement
        • VCU Massey Comprehensive Cancer Center
        • Chercheur principal:
          • Keri R. Maher
        • Contact:
    • Washington
      • Aberdeen, Washington, États-Unis, 98520
        • Suspendu
        • Providence Regional Cancer System-Aberdeen
      • Bellevue, Washington, États-Unis, 98004
        • Suspendu
        • Overlake Medical Center
      • Bellingham, Washington, États-Unis, 98225
        • Suspendu
        • PeaceHealth Saint Joseph Medical Center
      • Centralia, Washington, États-Unis, 98531
        • Suspendu
        • Providence Regional Cancer System-Centralia
      • Edmonds, Washington, États-Unis, 98026
        • Recrutement
        • Swedish Cancer Institute-Edmonds
        • Chercheur principal:
          • Alison K. Conlin
        • Contact:
      • Everett, Washington, États-Unis, 98201
        • Suspendu
        • Providence Regional Cancer Partnership
      • Issaquah, Washington, États-Unis, 98029
        • Suspendu
        • Swedish Cancer Institute-Issaquah
      • Kennewick, Washington, États-Unis, 99336
        • Suspendu
        • Kadlec Clinic Hematology and Oncology
      • Lacey, Washington, États-Unis, 98503
        • Suspendu
        • Providence Regional Cancer System-Lacey
      • Longview, Washington, États-Unis, 98632
        • Suspendu
        • PeaceHealth Saint John Medical Center
      • Port Townsend, Washington, États-Unis, 98368
        • Actif, ne recrute pas
        • Jefferson Healthcare
      • Renton, Washington, États-Unis, 98055
        • Suspendu
        • Valley Medical Center
      • Seattle, Washington, États-Unis, 98104
        • Suspendu
        • Pacific Gynecology Specialists
      • Seattle, Washington, États-Unis, 98107
        • Suspendu
        • Swedish Medical Center-Ballard Campus
      • Seattle, Washington, États-Unis, 98122-5711
        • Suspendu
        • Swedish Medical Center-Cherry Hill
      • Seattle, Washington, États-Unis, 98122
        • Recrutement
        • Swedish Medical Center-First Hill
        • Chercheur principal:
          • Alison K. Conlin
        • Contact:
      • Seattle, Washington, États-Unis, 98112
        • Actif, ne recrute pas
        • Kaiser Permanente Washington
      • Sedro-Woolley, Washington, États-Unis, 98284
        • Suspendu
        • PeaceHealth United General Medical Center
      • Shelton, Washington, États-Unis, 98584
        • Suspendu
        • Providence Regional Cancer System-Shelton
      • Vancouver, Washington, États-Unis, 98664
        • Suspendu
        • PeaceHealth Southwest Medical Center
      • Walla Walla, Washington, États-Unis, 99362
        • Suspendu
        • Providence Saint Mary Regional Cancer Center
      • Yakima, Washington, États-Unis, 98902
        • Suspendu
        • North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
      • Yelm, Washington, États-Unis, 98597
        • Suspendu
        • Providence Regional Cancer System-Yelm
    • Wisconsin
      • Ashland, Wisconsin, États-Unis, 54806
        • Suspendu
        • Northwest Wisconsin Cancer Center
      • Ashland, Wisconsin, États-Unis, 54806
        • Suspendu
        • Duluth Clinic Ashland
      • Hayward, Wisconsin, États-Unis, 54843
        • Suspendu
        • Essentia Health-Hayward Clinic
      • Madison, Wisconsin, États-Unis, 53792
        • Recrutement
        • University of Wisconsin Carbone Cancer Center - University Hospital
        • Chercheur principal:
          • Ryan J. Mattison
        • Contact:
      • Madison, Wisconsin, États-Unis, 53718
        • Recrutement
        • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
        • Chercheur principal:
          • Ryan J. Mattison
        • Contact:
      • Marshfield, Wisconsin, États-Unis, 54449
      • Milwaukee, Wisconsin, États-Unis, 53226
        • Recrutement
        • Medical College of Wisconsin
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 414-805-3666
        • Chercheur principal:
          • Guru Subramanian Guru Murthy
      • New Richmond, Wisconsin, États-Unis, 54017
        • Suspendu
        • Cancer Center of Western Wisconsin
      • Spooner, Wisconsin, États-Unis, 54801
        • Suspendu
        • Essentia Health-Spooner Clinic
      • Superior, Wisconsin, États-Unis, 54880
        • Suspendu
        • Essentia Health Saint Mary's Hospital - Superior
    • Wyoming
      • Cheyenne, Wyoming, États-Unis, 82001
        • Actif, ne recrute pas
        • Cheyenne Regional Medical Center-West
      • Cody, Wyoming, États-Unis, 82414
        • Suspendu
        • Billings Clinic-Cody
      • Sheridan, Wyoming, États-Unis, 82801
        • Suspendu
        • Welch Cancer Center

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 39 ans (Adulte)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

REGISTRATION ELIGIBILITY CRITERIA (STEP 1)

  • Newly diagnosed patients with CD-22 positive B-cell acute lymphoblastic leukemia (WHO criteria) are eligible. Patients with Burkitt type ALL are NOT eligible

  • REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Single-dose intrathecal cytarabine is allowed prior to registration or prior to initiation of systematic therapy for patient convenience; this is usually done at the time of the diagnostic bone marrow or venous line placement to avoid a second lumbar puncture; systemic chemotherapy must begin within 72 hours of this intrathecal therapy

  • REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Age >= 18 years and < 40 years

  • REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Eastern Cooperative Oncology Group (ECOG) performance status 0-2

  • REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN), unless suspected leukemic involvement of the liver

  • REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Direct bilirubin =< 3 x upper limit of normal (ULN), unless suspected leukemic involvement of the liver

  • REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Calculated (calc.) creatinine clearance >= 50 mL/min by Cockcroft-Gault

  • RANDOMIZATION ELIGIBILITY CRITERIA (STEP 2) CONFIRMATION OF TOLERABILITY AND PHASE III ONLY): Completion of remission induction therapy

  • RANDOMIZATION ELIGIBILITY CRITERIA (STEP 2) CONFIRMATION OF TOLERABILITY AND PHASE III ONLY):Patients with M2 marrow or better are eligible; patients with M3 or M4 marrow (greater than 25% lymphoblasts) will not be eligible to be randomized

    • Rating: M0, M1; Blast Cells (%): 0-5.0
    • Rating: M2; Blast Cells (%): 5.1-25.0
    • Rating: M3; Blast Cells (%): > 25-50
    • Rating: M4; Blast Cells (%): > 50.0
    • The term "blast cell" includes any cell that cannot be classified as a more mature normal element, and includes "leukemic cells," pathologic lymphocytes, and stem cells

  • RANDOMIZATION ELIGIBILITY CRITERIA (STEP 2) (CONFIRMATION OF TOLERABILITY AND PHASE III ONLY): Absolute neutrophil count (ANC) >= 750/mm^3

  • RANDOMIZATION ELIGIBILITY CRITERIA (STEP 2) (CONFIRMATION OF TOLERABILITY AND PHASE III ONLY): Platelet count >= 75,000/mm^3

  • RANDOMIZATION ELIGIBILITY CRITERIA (STEP 2) (CONFIRMATION OF TOLERABILITY AND PHASE III ONLY): Total bilirubin =< 1.5 x upper limit of normal (ULN), except for patients with known Gilbert's syndrome

  • RANDOMIZATION ELIGIBILITY CRITERIA (STEP 2) (CONFIRMATION OF TOLERABILITY AND PHASE III ONLY): Aspartate aminotransferase (AST) =< 8 x upper limit of normal (ULN)

EXCLUSION CRITERIA

  • REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients who have BCR-ABL fusion transcript determined by fluorescence in situ hybridization (FISH) or real time-polymerase chain reaction (RT-PCR) or t(9;22)(q34;q11) by cytogenetics are not eligible and should be considered for enrollment on studies that incorporate imatinib during induction; please note: patients must also be assessed for CD20 positivity and other markers; positivity for CD22 and CD20 is defined as baseline expression of the CD22 or CD20 antigen in more than 20% of leukemic cells using local multiparameter flow-cytometric immunophenotyping with the use of CD45 expression as a marker to gate the ALL blast population, according to recommendations from the European LeukemiaNet
  • REGISTRATION ELIGIBILITY CRITERIA (STEP 1): No prior therapy for ALL except for limited treatment (=< 7 days) with corticosteroids or hydroxyurea and a single dose of intrathecal cytarabine; however, patients who are being treated with chronic steroids for other reasons (for example, to treat asthma, autoimmune disorders, lupus, etc.) are eligible
  • REGISTRATION ELIGIBILITY CRITERIA (STEP 1): No prior therapy for acute leukemia except emergency therapy (corticosteroids or hydroxyurea) for blast cell crisis, superior vena cava syndrome, or renal failure due to leukemic infiltration of the kidneys; when indicated, leukapheresis or exchange transfusion is recommended to reduce the WBC
  • REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Not pregnant and not nursing, because this study involves agents that have known genotoxic, mutagenic and teratogenic effects; therefore, for women of childbearing potential only, a negative urine or serum pregnancy test done =< 8 days prior to registration is required
  • REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients with down syndrome are excluded from this study due to the likelihood of excessive toxicity resulting; these patients should be treated in consultation with a pediatric oncologist

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Arm I (frontline chemotherapy)

See detailed description.
Autre: Laboratory Biomarker Analysis

Correlative studies

Médicament: Cyclophosphamide

Given IV

Biologique: Rituximab

Given IV

Médicament: Vincristine Sulfate

Given IV

Médicament: Daunorubicin Hydrochloride

Given IV

Médicament: Mercaptopurine

Given PO

Médicament: Dexamethasone

Given PO or IV

Médicament: Thioguanine

Given PO

Médicament: Allopurinol

Given PO

Médicament: Cytarabine

Given IT, IV, SC

Médicament: Pegylated L-Asparaginase

Given IV

Médicament: Methotrexate

Given IT, IV, PO

Procédure: Bone Marrow Aspiration and Biopsy

Undergo bone marrow aspiration and biopsy
Expérimental: Arm II (frontline chemotherapy, inotuzumab ozogamicin)

Patients receive inotuzumab ozogamicin IV on days 1, 8, and 15 and undergo bone marrow aspirate and biopsy on day 28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients who are MRD+ and CD19+ after completion of 2 cycles of inotuzumab ozogamicin receive dexamethasone IV or PO on day 1 and blinatumomab IV via continuous infusion on days 1-28, followed by a 14 day break. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive remission consolidated chemotherapy, interim maintenance chemotherapy, delayed intensification, and maintenance therapy as in Arm I. Patients undergo MUGA or echocardiography and x ray imaging during screening, bone marrow aspiration and biopsy and lumbar puncture and blood sample collection throughout the study.
Autre: Laboratory Biomarker Analysis

Correlative studies

Médicament: Cyclophosphamide

Given IV

Médicament: Doxorubicin

Given IV

Biologique: Rituximab

Given IV

Médicament: Vincristine Sulfate

Given IV

Médicament: Daunorubicin Hydrochloride

Given IV

Médicament: Mercaptopurine

Given PO

Biologique: Inotuzumab Ozogamicin

Given IV

Médicament: Dexamethasone

Given PO or IV

Médicament: Thioguanine

Given PO

Médicament: Allopurinol

Given PO

Médicament: Cytarabine

Given IT, IV, SC

Médicament: Pegylated L-Asparaginase

Given IV

Médicament: Methotrexate

Given IT, IV, PO

Procédure: Bone Marrow Aspiration and Biopsy

Undergo bone marrow aspiration and biopsy

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Event-free survival (EFS)
Délai: Time from induction response to the time of progressive-disease, secondary malignancy, or death, assessed up to 3 years

The EFS distributions between the two arms will be compared using non-stratified log-rank tests. EFS curves will be constructed using the Kaplan-Meier product limit method, and additional analyses will be done using the Cox proportional hazards model. with diagnostics test on proportional hazard assumptions first. The corresponding hazard ratio, 2- and 3-year EFS estimates will be assessed, and EFS medians along with their 95% confidence intervals for the two treatment arms.
Time from induction response to the time of progressive-disease, secondary malignancy, or death, assessed up to 3 years

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Disease-free survival (DFS)
Délai: Time from achievement of complete response (CR) to the time of relapse and/or death, assessed up to 10 years
Time from achievement of complete response (CR) to the time of relapse and/or death, assessed up to 10 years
Overall Survival (OS)
Délai: Time from randomization to the time of death due to any cause, assessed up to 10 years

Will be evaluated using Kaplan-Meier as well as Cox regression models.
Time from randomization to the time of death due to any cause, assessed up to 10 years
Proportion of patients who achieve CR or any response to induction therapy
Délai: Up to 10 years

Will be summarized as the proportion of patients who achieve any type of response to induction therapy divided by the number of all evaluable patients registered to this trial and who received at least one dose of induction therapy. Corresponding 95% binomial confidence intervals will also be calculated.
Up to 10 years
Overall induction response rates
Délai: Up to 10 years

Will be summarized as the proportion of patients who achieve any type of response to induction therapy divided by the number of all evaluable patients registered to this trial and who received at least one dose of induction therapy. Corresponding 95% binomial confidence intervals will also be calculated.
Up to 10 years
Incidence of adverse events as assessed by Common Terminology Criteria for Adverse Events version 5.0
Délai: Up to 10 years

The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns. In addition, all adverse event data that is graded as 3, 4, or 5 will be reviewed and classified as either "unrelated" or "unlikely to be related" to study treatment in the event of an actual relationship developing. The incidence of severe (grade 3+) adverse events or toxicities will be described for each treatment arm, but will also be compared between the arms. Fisher's exact tests will be used to quantitatively compare the incidence of severe as well as specific toxicities of interest between the treatment arms and we will graphically assess differences in maximum grades observed for toxicities between the arms. Tolerability of the treatment arms will be assessed through assessing the number of patients who required dose modifications and/or dose delays.
Up to 10 years
Proportion of patients who go off treatment due to adverse reactions
Délai: Up to 10 years

Will be assessed within each of the treatment arms and differences explores in these measures between the arms.
Up to 10 years
Proportion of patients who refuse further treatment for lesser toxicities that inhibit their willingness to continue participation on the trial
Délai: Up to 10 years

Will be assessed within each of the treatment arms and differences explores in these measures between the arms.
Up to 10 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Alliance for Clinical Trials in Oncology

Collaborateurs

National Cancer Institute (NCI)

Les enquêteurs

  • Chaise d'étude: daniel_deangelo@dfci.harvard.edu J. DeAngelo, MD, PhD, Dana-Farber Cancer Institute

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

20 septembre 2017

Achèvement primaire (Estimé)

1 novembre 2027

Achèvement de l'étude (Estimé)

1 avril 2028

Dates d'inscription aux études

Première soumission

9 mai 2017

Première soumission répondant aux critères de contrôle qualité

10 mai 2017

Première publication (Réel)

12 mai 2017

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

3 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

2 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • A041501
  • U10CA180821 (Subvention/contrat des NIH des États-Unis)
  • NCI-2016-01981 (Identificateur de registre: Clinical Trial Reporting Program)

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner